Cold Urticaria: Hives from Cold Exposure

Clinical Overview

Cold Urticaria is a physical urticaria triggered by exposure to cold temperatures (air, water, or objects) that causes wheals and angioedema at sites of cold contact within minutes of rewarming skin. The condition is relatively common, affecting 0.5-5% of the population with any urticaria (making it the third-most common physical urticaria after dermatographism and cholinergic). Cold urticaria is of particular concern due to risk of systemic reactions: rapid rewarming of large body surface areas (such as jumping into warm water after cold water exposure) can trigger anaphylaxis with hypotension, syncope, or even death—a phenomenon called "cold-water immersion anaphylaxis" that has caused drownings. Early recognition and appropriate precautions are therefore critical.

Epidemiology & Risk Factors

Cold urticaria affects children and adults, with peak onset age 20-40 years. Approximately 50% of cases are idiopathic (primary), while 50% are associated with underlying systemic disease (secondary cold urticaria). Secondary cold urticaria associations include: cryoglobulinemia (particularly in hepatitis C), cold agglutinin disease (IgM autoantibodies against RBC), macroglobulinemia, lymphoma, syphilis, and tuberculosis. Therefore, patients with newly diagnosed cold urticaria warrant screening for underlying systemic disease. Risk factors for idiopathic cold urticaria include: genetic predisposition (positive family history in 10-20%), underlying atopy, elevated baseline tryptase levels, and prior viral infections (especially CMV, EBV). Prognosis varies: approximately 50% of patients with idiopathic cold urticaria remit within 5-10 years, while 30-40% have persistent symptoms for decades.

Pathophysiology

Cold-induced urticaria involves direct activation of mast cells and basophils via cold-sensitive ion channels and mechanoreceptors in skin. Cold exposure activates TRPM8 (transient receptor potential melastatin 8) channels on sensory nerve fibers and mast cells, triggering calcium influx and degranulation with histamine release. In secondary cold urticaria (cryoglobulinemia, cold agglutinin disease), circulating immune complexes precipitate in small vessels upon cold exposure, triggering complement activation and generating anaphylatoxins (C3a, C5a) that activate mast cells. Approximately 5-10% of cold urticaria is mediated by IgE autoantibodies against cold-modified autoantigens ("Cold-Specific IgE"), detected by basophil activation tests in research settings but not routinely clinically available. The rash develops upon REWARMING (not during cold exposure itself), as mast cell mediators are released as temperature normalizes.

Clinical Presentation & Classification

Cold urticaria presents with wheals and pruritus appearing on skin areas exposed to cold during the cold exposure or (more commonly) within 5 minutes of rewarming. Hands, lips, and face are most commonly affected when exposed to cold wind or cold water; trunk and legs affected if immersion in cold water. Individual lesions typically resolve within 30 minutes to 1 hour of rewarming. Associated angioedema occurs in 10-15% of cases, affecting lips, eyelids, or tongue. Importantly, systemic reactions can occur: rapid rewarming of large body surface area (e.g., jumping from cold water into warm water or a hot bath) causes massive mast cell degranulation, releasing sufficient histamine and other mediators to cause systemic symptoms: flushing, chest tightness, throat tightness, hypotension, and syncope (anaphylaxis). This has caused fatal drownings when patients develop syncope while in water.

Severity classification (based on cold challenge test response temperature):

• Mild: reaction at <15°C
• Moderate: reaction at 10-15°C
• Severe: reaction at >10°C (even brief exposure to mild cold triggers reactions)

Diagnosis & Workup

Diagnosis is confirmed by Ice Cube Test (Thermal Test): Apply ice cube to forearm for 5 minutes, then remove and observe for wheals over next 5-10 minutes. Wheals appearing confirm diagnosis. Alternative: immerse hand in cold water (4°C) for 5 minutes and observe for wheals. These tests reproduce the patient's symptoms and confirm diagnosis.

Workup for underlying systemic disease is essential:

• Complete blood count: Assess for lymphoma, evaluate RBC morphology (cold agglutinin disease may show RBC clumping)
• Comprehensive metabolic panel: Assess liver/kidney function
• Hepatitis C serology and cryoglobulin testing: Cryoglobulinemia present in 5-10% of cold urticaria; associated with hepatitis C in 80-90% of cryoglobulinemia cases
• Cold agglutinin titer: Elevated in cold agglutinin disease (1:512 or higher is significant)
• Serum protein electrophoresis and immunofixation: Screen for macroglobulinemia, monoclonal gammapath
• Rapid plasma reagin (RPR) or syphilis serology: Syphilis can associate with cold urticaria
• Chest imaging and TB testing: If symptoms or risk factors suggest tuberculosis
• Serum tryptase: Optional; elevated levels suggest mast cell predisposition

If initial screening is negative and patient has idiopathic cold urticaria, reassurance is appropriate. Repeat screening in 1-2 years if symptoms persist or worsen, as underlying disease may eventually declare itself.

Treatment Algorithm

First-line: Strict cold avoidance. This is critical and life-saving. Strategies: wear insulating gloves in cold weather, avoid rapid temperature changes, never immerse in cold water without warm water readily accessible, shower with warm (not hot) water to avoid rapid temperature changes, avoid swimming alone in cold water, and always have companions aware of cold urticaria who can assist if systemic reaction occurs. For severe cold urticaria, avoid exposure to cold weather entirely if possible.

Second-line: Second-generation H1 antihistamines. Cetirizine 10 mg daily or loratadine 10 mg daily. Efficacy: 40-50% experience improvement. Onset: 1-2 hours. Timing: take 30-60 minutes before anticipated cold exposure (e.g., before outdoor winter activities). Continuous dosing is superior to PRN dosing for frequent cold exposure.

If inadequate monotherapy: Increase to 2x standard dose (cetirizine 20 mg daily) or add H2-receptor antagonist (ranitidine/famotidine). Some data supports combined H1/H2 blockade providing additional efficacy.

Third-line agents (refractory cases):

• Omalizumab: 300 mg SC monthly. Variable efficacy (60-70% response in case series), allowing more normal cold exposure tolerance. Onset 4-8 weeks. Use reserved for severe cases limiting daily function despite antihistamines.
• Cyclosporine: 3-5 mg/kg/day. Requires monitoring (renal function, BP, drug interactions). Use reserved for severe, refractory cases.
• Combination therapy: Omalizumab + cyclosporine in very severe, treatment-resistant cases

Prognosis & Complications

Approximately 50% of patients with idiopathic cold urticaria achieve complete remission within 5-10 years; 30-40% have persistent symptoms indefinitely. Secondary cold urticaria (associated with systemic disease) may improve with treatment of underlying disease (e.g., hepatitis C treatment for cryoglobulinemia-associated cold urticaria). Major complications include: anaphylaxis with rapid rewarming of large body areas (potentially fatal, particularly in water leading to drowning), and systemic disease progression if secondary cold urticaria. Minor complications: frostbite risk from reduced sensation if skin becomes numb during cold exposure, and secondary infection from scratching.

When to See a Dermatologist

Seek evaluation if cold exposure consistently triggers wheals or angioedema. Dermatologists can confirm diagnosis with ice cube test, stratify severity, and initiate antihistamine or advanced therapy. Importantly, request evaluation for underlying systemic disease—many patients with cold urticaria harbor cryoglobulinemia, cold agglutinin disease, or malignancy that warrant treatment. Seek emergency care if you experience systemic symptoms (throat swelling, difficulty breathing, hypotension, syncope) after cold exposure.

Frequently Asked Questions

Why do I get hives from cold exposure?

Cold activates specialized ion channels (TRPM8) on mast cells in your skin. Unlike other people, your mast cells are exquisitely sensitive to this cold signal and release histamine in response. This is a genetically determined overreactivity—not due to poor immune system or anything you did. Approximately 50% of people with cold urticaria have underlying systemic disease (cryoglobulinemia, cold agglutinin disease), so screening is important.

Is it dangerous to have cold urticaria?

The wheals themselves are harmless, but rapid rewarming of large body areas (such as jumping from cold water into warm water or a hot bath) can trigger anaphylaxis: severe symptoms including throat swelling, difficulty breathing, and blood pressure drop. This can be fatal, particularly if it occurs while swimming. Therefore, avoid rapid temperature changes and never swim alone.

Can I ever go in cold water?

Yes, but with precautions. Gradual cold exposure (e.g., wading slowly into cold water) typically allows tolerance better than sudden immersion. However, when exiting, gradually warm up rather than jumping into hot water. Take an antihistamine 30-60 minutes before cold exposure to reduce symptoms. Wear protective gloves and clothing to minimize cold exposure. Swimming in cold water carries risk of anaphylaxis—avoid it entirely or only swim with a partner aware of your condition.

Will antihistamines cure cold urticaria?

Antihistamines suppress symptoms but do not cure the underlying mast cell sensitivity. However, 50% of people spontaneously improve or remit within 5-10 years. Antihistamines control symptoms well enough to allow safer cold exposure (with continued avoidance precautions) in many patients.

References